All Articles

Adaptive drug resistance in melanoma is characterised by lipidome remodelling while maintaining cell membrane biophysical properties

PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapy

Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation?

ST6GAL1 promotes cancer stem-like cell-associated paclitaxel resistance through the EGFR-mTOR-SOX2/BMI1 axis in non-small cell lung cancer

Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them

Divergent transcriptional programs and constrained metabolic states reveal selective metabolic dependencies in chemoresistant luminal breast cancer

Adenylosuccinate lyase in pancreatic ductal adenocarcinoma chemoresistance: from purine metabolism to metabolic vulnerability

Mitochondrial LINC01133 regulates pyroptosis and calcium homeostasis in cisplatin-resistant lung adenocarcinoma

TET2 downregulation limits oxidative stress-induced cytotoxicity of high dose ascorbate in dabrafenib-resistant melanoma cells

Mechanistic roles and clinical applications of tertiary lymphoid structures in colorectal cancer drug resistance

An epithelial-mesenchymal transition-related gene signature predicts prognosis, immune infiltration, and drug sensitivity in colorectal cancer

Lack of resolution of inflammation marks malignant pleural mesothelioma progression

LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62–Keap1–Nrf2 pathway

Unveiling the role of UGT enzymes in chemoresistance: a path to enhanced cancer pharmacotherapy

A systematic review and network meta analysis of first-line immunotherapy for advanced urothelial carcinoma

Fenretinide in cancer therapy and chemoprevention: past, present and future

Deep spatial proteomics reveals a suppressive immune niche linked to immune evasion in renal cell carcinoma

Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer